Nutritional and Botanical Approaches for Nonalcoholic Fatty Liver Disease

Perumpail BJ , Khan MA , Yoo ER , et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol, 2017; 23:8263–8276.

Pydyn N , Miękus K , Jura J , et al. New therapeutic strategies in nonalcoholic fatty liver disease: A focus on promising drugs for nonalcoholic steatohepatitis. Pharmacol Rep, 2020; 72:1–12.

Lazo M , Hernaez R , Eberhardt MS , et al. Prevalence of nonalcoholic fatty liver disease in the United States: The Third National. Am J Epidemiol, 2013; 178:38–45.

Paschos P , Paletas K . Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia, 2009; 13:9–19.

Leoni S , Tovoli F , Napoli L , et al. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol, 2018; 24:3361–3373.

Treeprasertsuk S , Björnsson E , Enders F , et al. NAFLD fibrosis score: A prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol, 2013; 19:1219–1229.

Kumar R , Teo EK , How HC , et al. A practical clinical approach to liver fibrosis. Singapore Med J, 2018; 59:628–633.

Tesfay M , Goldkamp WJ , Neuschwander-Tetri BA . NASH: The emerging most common form of chronic liver disease. Mo Med, 2018; 115:225–229.

Romero-Gómez M , Zelber-Sagi S , Trenell M . Treatment of NAFLD with diet, physical activity and exercise. J Hepatol, 2017; 67:829–846.

Tariq R , Axley P , Singal AK . Extra-hepatic manifestations of nonalcoholic fatty liver disease: A review. J Clin Exp Hepatol, 2020; 10:81–87.

Byrne CD , Targher G . NAFLD: A multisystem disease. J Hepatol, 2015; 62:S47–S64.

Kolodziejczyk AA , Zheng D , Shibolet O , et al. The role of the microbiome in NAFLD and NASH. EMBO Mol Med, 2019; 11:e9302.

George ES , Forsyth A , Itsiopoulos C , et al. Practical dietary recommendations for the prevention and management of nonalcoholic fatty liver disease in adults. Adv Nutr, 2018; 9:30–40.

Trovato FM , Catalano D , Martines GF , et al. Mediterranean diet and non-alcoholic fatty liver disease. The need of extended and comprehensive interventions. Clin Nutr, 2015; 34:86–88.

Gelli C , Tarocchi M , Abenavoli L , et al. Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease. World J Gastroenterol, 2017; 23:3150–3162.

Ryan MC , Itsiopoulos C , Thodis T , et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol, 2013; 59:138–143.

Nishi T , Babazono A , Maeda T , et al. Effects of eating fast and eating before bedtime on the development of nonalcoholic fatty liver disease. Popul Health Manag, 2016; 19:279–283.

Bo S , Musso G , Beccuti G , et al. Consuming more of daily caloric intake at dinner predisposes to obesity. A 6-year population-based prospective cohort study. PLoS One, 2014; 9:e108467.

El-Agroudy NN , Kurzbach A , Rodionov RN , et al. Are lifestyle therapies effective for NAFLD treatment?. Trends Endocrinol Metab, 2019; 30:701–709.

Mazzoccoli G , De Cosmo S , Mazza T . The biological clock: A pivotal hub in non-alcoholic fatty liver disease pathogenesis. Front Physiol, 2018; 9:193.

Johari MI , Yusoff K , Haron J , et al. A randomised controlled trial on the effectiveness and adherence of modified alternate-day calorie restriction in improving activity of non-alcoholic fatty liver disease. Sci Rep, 2019; 9:11232.

Cai H , Qin YL , Shi ZY , et al. Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: A randomised controlled trial. BMC Gastroenterol, 2019; 19:219.

White JS. Straight talk about high-fructose corn syrup: What it is and what it ain't. Am J Clin Nutr, 2008; 88:1716S–1721S.

Basaranoglu M , Basaranoglu G , Bugianesi E . Carbohydrate intake and nonalcoholic fatty liver disease: Fructose as a weapon of mass destruction. Hepatobiliary Surg Nutr, 2015; 4:109–10916.

Duffey KJ , Popkin BM . High-fructose corn syrup: Is this what's for dinner?. Am J Clin Nutr, 2008; 88:1722S.

Assy N , Nasser G , Kamayse I , et al. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can J Gastroenterol, 2008; 22:811.

Wijarnpreecha K , Thongprayoon C , Edmonds PJ . Associations of sugar- and artificially sweetened soda with nonalcoholic fatty liver disease: A systematic review and meta-analysis. QJM, 2016; 109:461–466.

Chen H , Wang J , Li Z , et al. Consumption of sugar-sweetened beverages has a dose-dependent effect on the risk of non-alcoholic fatty liver disease: An updated systematic review and dose-response meta-analysis. Int J Environ Res Public Health, 2019; 16:21.

Schwimmer JB , Ugalde-Nicalo P , Welsh JA , et al. Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: A randomized clinical trial. JAMA, 2019; 321:256–265.

Green CH , Syn WK . Non-nutritive sweeteners and their association with the metabolic syndrome and non-alcoholic fatty liver disease: A review of the literature. Eur J Nutr, 2019; 58:1785–1800.

Suez J , Korem T , Zeevi D , et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature, 2014; 514:181–186.

Finamor I , Pérez S , Bressan CA , et al. Chronic aspartame intake causes changes in the trans-sulphuration pathway, glutathione depletion and liver damage in mice. Redox Biol, 2017; 11:701–707.

Liu W , Baker S , Baker R , et al. Antioxidant mechanisms in nonalcoholic fatty liver disease. Curr Drug Targets, 2015; 16:1301–1314.

Dou X , Li S , Hu L , et al. Glutathione disulfide sensitizes hepatocytes to TNFα-mediated cytotoxicity via IKK-β S-glutathionylation: A potential mechanism underlying non-alcoholic fatty liver disease. Exp Mol Med, 2018; 50:1–16.

Nseir W , Nassar F , Assy N . Soft drinks consumption and nonalcoholic fatty liver disease. World J Gastroenterol, 2010; 16:2579–2588.

Marventano S , Salomone F , Godos J , et al. Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies. Clin Nutr, 2016; 35:1269–1281.

Wijarnpreecha K , Thongprayoon C , Ungprasert P . Coffee consumption and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. Eur J Gastroenterol Hepatol, 2017; 29:e8–e12.

Wiedeman AM , Barr SI , Green TJ , et al. Dietary choline intake: Current state of knowledge across the life cycle. Nutrients, 2018; 10:1513.

Sherriff JL , O'Sullivan TA , Properzi C , et al. Choline, its potential role in nonalcoholic fatty liver disease, and the case for human and bacterial genes. Adv Nutr, 2016; 7:5–13.

Buchman AL , Ament ME , Sohel M , et al. Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: Proof of a human choline requirement: A placebo-controlled trial. JPEN J Parenter Enteral Nutr, 2001; 25:260–268.

Mazidi M , Katsiki N , Mikhailidis DP , et al. Adiposity may moderate the link between choline intake and non-alcoholic fatty liver disease. J Am Coll Nutr, 2019; 38:633–639.

Safari Z , Gérard P . The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci, 2019; 76:1541–1558.

Spencer MD , Hamp TJ , Reid RW , et al. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology, 2011; 140:976–986.

Tilg H , Burcelin R , Tremaroli V . Liver tissue microbiome in NAFLD: Next step in understanding the gut-liver axis?. Gut, 2020; 69:1373–1374.

Shanab AA , Scully P , Crosbie O , et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: Association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci, 2011; 56:1524–1534.

Bakhshimoghaddam F , Shateri K , Sina M HM . Daily consumption of synbiotic yogurt decreases liver steatosis in patients with nonalcoholic fatty liver disease: A randomized controlled clinical trial. J Nutr, 2018; 148:1276–1284.

Nabavi S , Rafraf M , Somi MH , et al. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. J Dairy Sci, 2014; 97:7386–7393.

Kobyliak N , Abenavoli L , Mykhalchyshyn G , et al. A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: Evidence from a randomized clinical trial. J Gastrointest Liver Dis, 2018; 27:41–49.

Aller R , De Luis DA , Izaola O CR . Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial. Eur Rev Med Pharmacol Sci, 2011; 15:1090–1095.

Manzhalii E , Virchenko O , Falalyeyeva T , et al. Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: A pilot trial. J Dig Dis, 2017; 18:698–703.

Amanullah I , Khan YH , Anwar I , et al. Effect of Vitamin E in non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomised controlled trials. Postgrad Med J, 2019; 95:601–611.

Jiang Q. Natural forms of vitamin E: Metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. Free Radic Biol Med, 2014; 72:76–90.

Muid S , Ali Yusoff , et al. Optimal antioxidant activity with moderate concentrations of Tocotrienol rich fraction (TRF) in in vitro assays. Int Food Res J, 2013; 20:687–694.

Rizvi S , Raza ST , Ahmed F , et al. The role of Vitamin E in human health and some diseases. Sultan Qaboos Univ Med J, 2014; 14:e157.

Pervez MA , Khan DA , Ijaz A , et al. Effects of delta-tocotrienol supplementation on liver enzymes, inflammation, oxidative stress and hepatic steatosis in patients with nonalcoholic fatty liver disease. Turk J Gastroenterol, 2018; 29:170–176.

Larion S , Khurana S . Clinical studies investigating the effect of vitamin E therapy in patients with NASH. Clin Liver Dis, 2018; 11:16–21.

Pakravan H , Ahmadian M , Fani A , et al. The effects of melatonin in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Adv Biomed Res, 2017; 6:40.

Gonciarz M , Gonciarz Z , Bielanski W , et al. The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: A pilot study. J Physiol Pharmacol, 2012; 63:35–40.

Panahi Y , Kianpour P , Mohtashami R , et al. Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: A pilot double-blind randomized controlled trial. Phyther Res, 2018; 32:1382–1387.

Zhong S , Fan Y , Yan Q , et al. The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trials. Medicine, 2017; 96:e9061.

Vargas-Mendoza N , Madrigal-Santillán E , Morales-González Á, et al. Hepatoprotective effect of silymarin. World J Hepatol, 2014; 6:144–149.

Wah Kheong C , Nik Mustapha NR , Mahadeva S . A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol, 2017; 15:1940.e8–1949.e8.

Navarro VJ , Belle SH , D'Amato M , et al. Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial. PLoS One, 2019; 14:e0221683.

Khan H , Ullah H , Nabavi SM . Mechanistic insights of hepatoprotective effects of curcumin: Therapeutic updates and future prospects. Food Chem Toxicol, 2019; 124:182–191.

Mirhafez SR , Farimani AR , Dehhabe M , et al. Effect of phytosomal curcumin on circulating levels of adiponectin and leptin in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled clinical trial. J Gastrointestin Liver Dis, 2019; 28:183–189.

Maev I V. , Samsonov AA , Palgova LK , et al. Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities (MANPOWER study). BMJ Open Gastroenterol, 2020; 7:341.

Mansour-Ghanaei F , Pourmasoumi M , Hadi A , et al. Efficacy of curcumin/turmeric on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review of randomized controlled trials. Integr Med Res, 2019; 8:57–61.

Yan HM , Xia MF , Wang Y , et al. Efficacy of berberine in patients with non-alcoholic fatty liver disease. PLoS One, 2015; 10:e0134172.

Chang X , Wang Z , Zhang J , et al. Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease. J Transl Med, 2016; 14:266.